Tagraxofusp, the first CD123-targeted therapy and first targeted treatment for blastic plasmacytoid dendritic cell neoplasm

Tagraxofusp in Blastic Plasmacytoid Dendritic-Cell Neoplasm

(2019) Naveen Pemmaraju et al.   NEW ENGLAND JOURNAL OF MEDICINE

The interleukin-3 receptor CD123 targeted SL-401 mediates potent cytotoxic activity against CD34 + CD123 + cells from acute myeloid leukemia / myelodysplastic syndrome patients and healthy donors

(2018) Rajeswaran Mani et al.   HAEMATOLOGICA

The interleukin-3 receptor CD123 targeted SL-401 mediates potent cytotoxic activity against CD34 + CD123 + cells from acute myeloid leukemia / myelodysplastic syndrome patients and healthy donors

(2018) Rajeswaran Mani et al.   HAEMATOLOGICA

Venetoclax in a Patient with a Blastic Plasmacytoid Dendritic-Cell Neoplasm

(2018) Mounzer E. Agha et al.   NEW ENGLAND JOURNAL OF MEDICINE

A novel agent SL-401 induces anti-myeloma activity by targeting plasmacytoid dendritic cells, osteoclastogenesis and cancer stem-like cells

(2017) A Ray et al.   LEUKEMIA

The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia

(2016) D. A. Arber et al.   BLOOD

Blastic Plasmacytoid Dendritic Cell Neoplasm Is Dependent on BCL2 and Sensitive to Venetoclax

(2016) Joan Montero et al.   Cancer Discovery

Classification and clinical behavior of blastic plasmacytoid dendritic cell neoplasms according to their maturation-associated immunophenotypic profile

(2015) Lourdes Martín-Martín et al.   Oncotarget

Activity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patients

(2014) A. E. Frankel et al.   BLOOD

SL-401 and SL-501, targeted therapeutics directed at the interleukin-3 receptor, inhibit the growth of leukaemic cells and stem cells in advanced phase chronic myeloid leukaemia

(2014) Olga Frolova et al.   BRITISH JOURNAL OF HAEMATOLOGY

In vivo and in vitro sensitivity of blastic plasmacytoid dendritic cell neoplasm to SL-401, an interleukin-3 receptor targeted biologic agent

(2014) F. Angelot-Delettre et al.   HAEMATOLOGICA

TET2mutations, myelodysplastic features, and a distinct immunoprofile characterize blastic plasmacytoid dendritic cell neoplasm in the bone marrow

(2013) Khaled Alayed et al.   AMERICAN JOURNAL OF HEMATOLOGY

Blastic plasmacytoid dendritic cell neoplasm with leukemic presentation: an Italian multicenter study

(2013) L. Pagano et al.   HAEMATOLOGICA

Roman-Gomez J, Cordeu L, Agirre X, Jimenez-Velasco A, San Jose-Eneriz E, Garate L, Calasanz MJ, Heiniger A, Torres A, Prosper F. Epigenetic regulation of Wnt-signaling pathway in acute lymphoblastic leukemia. Blood. 2007;109(8):3462-3469.

(2012)   BLOOD

A diphtheria toxin interleukin-3 fusion protein synergizes with tyrosine kinase inhibitors in killing leukemic progenitors from BCR/ABL positive acute leukemia

(2010) Hyun Pyo Kim et al.   LEUKEMIA RESEARCH

Blastic plasmacytoid dendritic cell neoplasm: is transplantation the treatment of choice?

(2009) S. Dalle et al.   BRITISH JOURNAL OF DERMATOLOGY

Extended diagnostic criteria for plasmacytoid dendritic cell leukaemia

(2009) Francine Garnache-Ottou et al.   BRITISH JOURNAL OF HAEMATOLOGY

Functional Interaction of Plasmacytoid Dendritic Cells with Multiple Myeloma Cells: A Therapeutic Target

(2009) Dharminder Chauhan et al.   CANCER CELL

Overexpression of CD123 correlates with the hyperdiploid genotype in acute lymphoblastic leukemia

(2009) M. Djokic et al.   HAEMATOLOGICA

Phase I clinical study of diphtheria toxin-interleukin 3 fusion protein in patients with acute myeloid leukemia and myelodysplasia

(2008) Arthur Frankel et al.   LEUKEMIA & LYMPHOMA